A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

Michael C. Sneller, J. Shawn Justement, Kathleen Gittens, +18

Science Translational Medicine

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

Timothy Fouts, Kenneth Bagley, Ilia Prado, +19

Proceedings of the National Academy of Sciences

Hiv VaccinesCandidate Hiv VaccineImmunologyDouble-edged SwordCd4 T Cell Responses +14

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Chad E. Mire, Demetrius Matassov, Joan B. Geisbert, +9

Nature

VaccinationMucosal VaccinationVaccine DevelopmentVaccine TargetEbola Makona Virus +6

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Marnie Elizaga, Shuying S. Li, Nidhi Kochar, +16

PLoS ONE

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge

Demetrius Matassov, Chad E. Mire, Theresa Latham, +13

Journal of Virology

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA

Shuying S. Li, Nidhi Kochar, Marnie Elizaga, +22

Clinical and Vaccine Immunology

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

David K. Clarke, Rong Xu, Demetrius Matassov, +14

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology +3

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses

Shakuntala Megati, Dorys Garcia-Hand, Sarah Cappello, +15

Vaccine

Human RetrovirusImmunologyAntiviral ResponseChronic Viral InfectionVaccine Design +3

An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model

Kenneth Bagley, Jennifer A. Schwartz, Hanné Andersen, +6

Viral Immunology

VaccinationVaccine DevelopmentVaccine ResearchEffective Hsv-2 VaccineVaccine Target +13

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, +14

Molecular Therapy — Oncolytics